Dr. Seth Lederman, MD, CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP) (“Tonix”), talks with New to The Street’s TV Host Jane King about the Company’s progress on a treatment for Long-Covid. Dr. Lederman tells viewers that data from its FDA Phase 2 proof-of-concept PREVAIL study of TNX-102 SL shows top-line results in combating fatigue. Millions of Americans are experiencing fatigue issues from their COVID-19 infections. The Company needs more studies to bring the product to market once it obtains regulatory guidelines. US FDA and Health and Human Services (HHS) are looking into regulatory fast-track options, which are a must to bring products like TNXP’s TNX-102 SL Long-Covid to market sooner, helping many overcome the fatigue onsets. Once FDA-approved, many patients with fatigue associated with Long-COVID will benefit from a comprehensive treatment. Tonix Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical Company that aims to improve health by innovating vaccines and therapies. The on-screen QR code is available during the shows; download or visit Tonix Pharmaceuticals, Inc. – https://www.tonixpharma.com/.
To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/c/newtothestreettv
Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/
Follow New to the Street on Rumble: https://rumble.com/user/newtothestreet
About New to the Street: https://www.newtothestreet.com/
Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list